Seeking a savvy business developer with multiple years hands-on trading experience.

 

Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

Downloadable fact sheet answering the most common question TheSocialMedwork asked by healthcare providers.

In recognition of Rare Disease Day, our colleague, Sera, shares her story of her dad's fight with Multiple System Atrophy (MSA). 

Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

Teresa's husband was diagnosed with ALS. She spent 11 years as his caregiver and discusses her experiences.